Author:
Scheen André J,Radermecker Régis P
Reference14 articles.
1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006
2. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6);Buse;Lancet,2009
3. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study;Drucker;Lancet,2008
4. Bergenstal R, Wysham C, Ping Y, Macconell L, Malloy J, Porter L. DURATION-2: exenatide once weekly demonstrated superior glycemic control and weight reduction compared to sitagliptin and pioglitazone after 26 weeks of treatment. 69th Scientific Sessions of the American Diabetes Association; New Orleans, LA, USA; June 5–9, 2009. Abstr 6-LB.
5. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes;Nathan;Diabetologia,2009
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献